Joel takes a look at PATHWAY-2 from 2014. This is one landmark articles in hypertension. You should know it.
New player in resistant hypertension?
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!